Search

Your search keyword '"Yasumatsu, Ryuji"' showing total 135 results
Start Over Author "Yasumatsu, Ryuji" Search Limiters Full Text
135 results on '"Yasumatsu, Ryuji"'

5. The Usefulness of Total Laryngectomy in Sarcopenic Patients With Hypopharyngeal and Laryngeal Cancer

Author

KITANO, MUTSUKAZU, KOIKE, SATORU, TAMAKI, HISATOMO, IWAMOTO, SHUSUKE, MIYAMOTO, KAZUHIRO, OHIRA, NORIKO, KIMURA, TAKAYUKI, SATO, MITSUO, and YASUMATSU, RYUJI

Subjects
Research Article
Abstract

Background/Aim: Sarcopenia has an adverse effect on postoperative complications and prognoses in head and neck cancer. This study focused on hypopharyngeal and laryngeal cancer patients with sarcopenia and analyzed the body composition following treatment when the larynx was preserved and when total laryngectomy was performed to examine the usefulness of laryngectomy. Patients and Methods: We retrospectively reviewed 88 primary hypopharyngeal and laryngeal cancer patients aged 65 years or older with cT2N0M0 or higher who visited our department. Results: There were no significant differences in the 3-year overall survival rate and the 1-year local control rate between the laryngeal preservation group and laryngectomy group. The average change one year following treatment in the laryngeal preservation group, when compared to prior to treatment, was a significant decrease in the body weight (BW) of -0.035, skeletal muscle mass (SMM) of -0.030, skeletal muscle mass index (SMI) of -0.026, body mass index (BMI) of -0.034, and grip strength (GS) of -0.066. The average change one year following treatment in the laryngectomy group, compared with prior to treatment, was an increase in BW of +0.028, SMM of +0.026, SMI of +0.008, BMI of +0.032, and GS of +0.026. Although no changes in serum biochemical testing after treatment were observed in the laryngeal preservation group, albumin, transferrin, and transthyretin all exhibited significant improvement or a tendency toward improvement in the laryngectomy group. The patients with sarcopenia before treatment in the laryngeal preservation group had a significantly higher incidence of aspiration pneumonia. Conclusion: The presence or absence of sarcopenia before starting treatment is considered to be an index for selecting total laryngectomy.

Published
2023

6. Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights

Author

WAKASAKI, TAKAHIRO, YASUMATSU, RYUJI, TANABE, MIKA, YOSHIKAWA, HIROSHI, JIROMARU, RINA, HASHIMOTO, KAZUKI, MATSUO, MIOKO, FUJIMURA, AKIKO, and NAKAGAWA, TAKASHI

Subjects
Pharmacology, Cancer Research, General Biochemistry, Genetics and Molecular Biology, Research Article
Abstract

Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15, 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases.

Published
2023

7. Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib

Author

Nio, Kenta, Tsuchihashi, Kenji, Taguchi, Keisuke, Yoshihiro, Tomoyasu, Yamaguchi, Kyoko, Ito, Mamoru, Moriyama, Shohei, Fukata, Mitsuhiro, Fujiwara, Toshifumi, Setsu, Nokitaka, Endo, Makoto, Matsumoto, Yoshihiro, Nakashima, Yasuharu, Wakasaki, Takahiro, Yasumatsu, Ryuji, Ariyama, Hiroshi, Kusaba, Hitoshi, Kishimoto, Junji, Akashi, Koichi, and Baba, Eishi

Published
2020
Full Text
View/download PDF

9. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options

Author

Jiromaru,Rina, Nakagawa,Takashi, and Yasumatsu,Ryuji

Subjects
Cancer Management and Research
Abstract

Rina Jiromaru,1 Takashi Nakagawa,1 Ryuji Yasumatsu2 1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Kindai University, Osaka, JapanCorrespondence: Ryuji Yasumatsu, Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Kindai University, 377-2 Onohigashi, Osaka, 589-0014, Japan, Tel +81-72-3660221, Fax +81-72-3682252, Email ryuji.yasumatsu@med.kindai.ac.jpAbstract: Nasopharyngeal carcinoma (NPC) has seen improved treatment outcomes and a decrease in incidence worldwide in recent years due to developments in medicine and improved public health. However, 70% of cases are still diagnosed at advanced stages and these advanced NPC cases show a poor prognosis. Reports on current and future treatment in advanced NPC are summarized. Chemoradiotherapy is the mainstay of treatment for advanced NPC. The administration of platinum agents as a concurrent drug and intensity modulated radiotherapy (IMRT) is the most appropriate irradiation method, and is associated with high local control rates. For induction and adjuvant chemotherapy, platinum-based two- or three-drug combination chemotherapy is recommended. The tumour volume, plasma Epstein-Barr virus (EBV)-DNA levels, and the tumour site are used to determine the indication for adjuvant and neo-adjuvant chemotherapy. The tolerability of induction chemotherapy is controversial, and the indications and timing should be carefully considered in each case. Chemotherapy is used for patients with distant metastasis. Gemcitabine/cisplatin is the first-line regimen. The efficacy of immune checkpoint inhibitor (ICI) treatment has recently been reported for NPC and, as in other areas of the head and neck, it is expected to be effective for patients with recurrent/distant metastasis. Trials are underway for various uses of ICIs, including induction chemotherapy, postoperative treatment, and use in combination with chemoradiotherapy. Immunotherapy for NPC, an EBV-associated cancer, has been reported to have some efficacy with immunotherapy used in other EBV-associated cancers. Immunotherapy may be introduced for NPC in the future, depending on the results of clinical trials. Future changes in the treatment of NPC are expected to include risk classification based on plasma EBV-DNA levels and the development of personalized treatment with individual selection of timing and type of therapy.Keywords: nasopharyngeal carcinoma, therapy, Epstein-Barr virus

Published
2022

11. Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis.

Author

Yasumatsu, Ryuji, Manako, Tomomi, Jiromaru, Rina, Hashimoto, Kazuki, Wakasaki, Takahiro, Matsuo, Mioko, and Nakagawa, Takashi

Subjects
*HEAD & neck cancer diagnosis, *HEAD & neck cancer treatment, *HEAD & neck cancer, *RETROSPECTIVE studies, *EARLY detection of cancer, *TUMOR classification, *CANCER patients, *SURVIVAL rate, *TREATMENT effectiveness, *DESCRIPTIVE statistics, *RESEARCH funding, *ENDOSCOPIC gastrointestinal surgery, *SQUAMOUS cell carcinoma, *HYPOPHARYNGEAL cancer, *DISEASE management, *DISEASE complications, LARYNGEAL tumors
Abstract

Objective: Early detection of hypopharyngeal squamous cell carcinoma (SCC) is important for both an improved prognosis and less-invasive treatment. We retrospectively analyzed the detection rates of early hypopharyngeal SCCs according to the evaluation methods and the clinical management of early hypopharyngeal SCCs. Methods: Sixty-eight patients with early hypopharyngeal SCC who were diagnosed were reviewed. Results: The number of early hypopharyngeal cancer patients with asymptomatic or synchronous or metachronous esophageal cancer examined by upper gastrointestinal endoscopy with narrow-band imaging (NBI) was significantly higher than those examined by laryngopharyngeal endoscopy with NBI. The 3-year disease-specific survival rates according to T classification were as follows: Tis, 100%; T1, 100%; T2, 79.8%; and overall, 91.2%, respectively. Conclusions: Early-stage hypopharyngeal SCC can be cured by minimally invasive transoral surgery or radiotherapy. Observation of the pharynx using NBI in patients with a history of head and neck cancer, esophageal cancer, gastric cancer, or pharyngeal discomfort is very important, and routinely examining the pharynx with NBI, even in patients undergoing endoscopy for screening purposes, is recommended. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

Author

Wakasaki, Takahiro, primary, Manako, Tomomi, additional, Yasumatsu, Ryuji, additional, Hara, Hirotaka, additional, Toh, Satoshi, additional, Masuda, Muneyuki, additional, Yamauchi, Moriyasu, additional, Kuratomi, Yuichiro, additional, Nishimura, Emi, additional, Takeuchi, Toranoshin, additional, Matsuo, Mioko, additional, Jiromaru, Rina, additional, Hashimoto, Kazuki, additional, Komune, Noritaka, additional, and Nakagawa, Takashi, additional

Published
2022
Full Text
View/download PDF

13. Abstract 5210: Tumor immune characterization identifies age-stratified biomarkers for nivolumab in patients with head and neck squamous cell carcinoma: A nationwide collaborative study in Japan

Author

Tsujikawa, Takahiro, primary, Ohno, Kazuchika, additional, Saburi, Sumiyo, additional, Mitsuda, Junichi, additional, Yoshimura, Kanako, additional, Kimura, Alisa, additional, Morimoto, Hiroki, additional, Ohmura, Gaku, additional, Arai, Akihito, additional, Ogi, Hiroshi, additional, Shibata, Saya, additional, Ariizumi, Yosuke, additional, Tasaki, Akihisa, additional, Takahashi, Ryosuke, additional, Tateishi, Yumiko, additional, Kawabe, Hiroaki, additional, Ikeda, Sadakatsu, additional, Morita, Kei-ichi, additional, Tsunoda, Tatsuhiko, additional, Akashi, Takumi, additional, Kurata, Morito, additional, Imoto, Issei, additional, Shimizu, Yasushi, additional, Watanabe, Akihito, additional, Asada, Yukinori, additional, Hayashi, Ryuichi, additional, Saito, Yuki, additional, Ozawa, Hiroyuki, additional, Tsukahara, Kiyoaki, additional, Oridate, Nobuhiko, additional, Horii, Arata, additional, Maruo, Takashi, additional, Hanai, Nobuhiro, additional, Inohara, Hidenori, additional, Iwai, Hiroshi, additional, Fujii, Takashi, additional, Nibu, Ken-ichi, additional, Iwae, Shigemichi, additional, Ueda, Tsutomu, additional, Yasumatsu, Ryuji, additional, Umeno, Hirohito, additional, Masuda, Muneyuki, additional, Itoh, Kyoko, additional, Hirano, Shigeru, additional, and Asakage, Takahiro, additional

Published
2022
Full Text
View/download PDF

16. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

Author

NAKANO, TAKAFUMI, primary, YASUMATSU, RYUJI, additional, HASHIMOTO, KAZUKI, additional, KUGA, RYOSUKE, additional, HONGO, TAKAHIRO, additional, YAMAMOTO, HIDETAKA, additional, MATSUO, MIOKO, additional, WAKASAKI, TAKAHIRO, additional, JIROMARU, RINA, additional, MANAKO, TOMOMI, additional, TOH, SATOSHI, additional, MASUDA, MUNEYUKI, additional, YAMAUCHI, MORIYASU, additional, KURATOMI, YUICHIRO, additional, URYU, HIDEOKI, additional, NAKASHIMA, TORAHIKO, additional, TAMAE, AKIHIRO, additional, TANAKA, RISA, additional, TAURA, MASAHIKO, additional, TAKEUCHI, TORANOSHIN, additional, YOSHIDA, TAKAMASA, additional, and NAKAGAWA, TAKASHI, additional

Published
2022
Full Text
View/download PDF

20. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting

Author

Kariya, Shin, Shimizu, Yasushi, Hanai, Nobuhiro, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Yoshida, Masafumi, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Yonekura, Shuji, Asakage, Takahiro, Fujiwara, Akinori, Yamada, Takayuki, 1000030312359, Homma, Akihiro, Kariya, Shin, Shimizu, Yasushi, Hanai, Nobuhiro, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Yoshida, Masafumi, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Yonekura, Shuji, Asakage, Takahiro, Fujiwara, Akinori, Yamada, Takayuki, 1000030312359, and Homma, Akihiro

Abstract

Background To examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer. Methods Data on the effectiveness of nivolumab were extracted from patient medical records. All patients were analyzed for effectiveness by prior cetuximab use. In the analyses for prior neck dissection, only patients with locally advanced disease were included. Results Of 256 patients analyzed, 155 had received prior cetuximab. Nineteen of 50 patients with local recurrence underwent neck dissection. The objective response rate was 14.7 vs 17.2% (p = 0.6116), median progression-free survival was 2.0 vs 3.1 months (p = 0.0261), and median overall survival was 8.4 vs 12 months (p = 0.0548) with vs without prior cetuximab use, respectively. The objective response rate was 23.1 vs 25.9% (p = 0.8455), median progression-free survival was 1.8 vs 3.0 months (p = 0.6650), and median overall survival was 9.1 vs 9.9 months (p = 0.5289) with vs without neck dissection, respectively. Conclusions These findings support the use of nivolumab for patients with recurrent/metastatic head and neck cancer regardless of prior cetuximab use or neck dissection history.

Published
2021

21. Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study

Author

Yasumatsu, Ryuji, 1000010374513, Shimizu, Yasushi, Hanai, Nobuhiro, Kariya, Shin, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Ando, Mizuo, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, 1000080550368, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Yonekura, Syuji, Asakage, Takahiro, Nekado, Takahiro, Yamada, Takayuki, 1000030312359, Homma, Akihiro, Yasumatsu, Ryuji, 1000010374513, Shimizu, Yasushi, Hanai, Nobuhiro, Kariya, Shin, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Ando, Mizuo, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, 1000080550368, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Yonekura, Syuji, Asakage, Takahiro, Nekado, Takahiro, Yamada, Takayuki, 1000030312359, and Homma, Akihiro

Abstract

Background We have previously reported the effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) in real-world clinical practice in Japan. Here, we report long-term outcomes from this study in the overall population and subgroups stratified by subsequent chemotherapy. Methods In this multicenter, retrospective observational study, Japanese patients with recurrent or metastatic (R/M) HNC receiving nivolumab were followed up for 2 years. Effectiveness endpoints included overall survival (OS), OS rate, progression-free survival (PFS), and PFS rate. Safety endpoints included the incidence of immune-related adverse events (irAEs). Results Overall, 256 patients received a median of 6.0 doses (range: 1-52) of nivolumab over a median duration of 72.5 days (range: 1-736). Median OS was 9.5 months [95% confidence interval (CI) 8.2-12.0] and median PFS was 2.1 months (95% CI 1.8-2.7). A significant difference between 2-year survivors (n = 62) and non-2-year survivors was observed by median age (P = 0.0227) and ECOG PS (P = 0.0001). Of 95 patients who received subsequent chemotherapy, 54.7% received paclitaxel +/- cetuximab. The median OS and PFS from the start of paclitaxel +/- cetuximab were 6.9 months (95% CI 5.9-11.9) and 3.5 months (95% CI 2.3-5.5), respectively. IrAEs were reported in 17.2% of patients. Endocrine (7.0%) and lung (4.3%) disorders were the most common irAEs; kidney disorder (n = 1) was newly identified in this follow-up analysis. Conclusions Results demonstrated the long-term effectiveness of nivolumab and potential effectiveness of subsequent chemotherapy in patients with R/M HNC in the real-world setting. Safety was consistent with that over the 1-year follow-up.

Published
2021

22. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice : a multicenter retrospective clinical study

Author

1000080381797, Hanai, Nobuhiro, 1000010374513, Shimizu, Yasushi, 1000010274226, Kariya, Shin, 1000000444787, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, 1000080396754, Yoshida, Masafumi, Hanyu, Kenji, 1000070522928, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, 1000070449916, Ono, Takeharu, Sano, Daisuke, 1000030572838, Yamauchi, Moriyasu, Watanabe, Akihito, 1000010233272, Omori, Koichi, Yamazaki, Tomoko, 1000040501846, Monden, Nobuya, 1000030770143, Kudo, Naomi, Arai, Makoto, Sakurai, Daiju, 1000050361481, Asakage, Takahiro, Doi, Issei, Yamada, Takayuki, 1000030312359, Homma, Akihiro, 1000080381797, Hanai, Nobuhiro, 1000010374513, Shimizu, Yasushi, 1000010274226, Kariya, Shin, 1000000444787, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, 1000080396754, Yoshida, Masafumi, Hanyu, Kenji, 1000070522928, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, 1000070449916, Ono, Takeharu, Sano, Daisuke, 1000030572838, Yamauchi, Moriyasu, Watanabe, Akihito, 1000010233272, Omori, Koichi, Yamazaki, Tomoko, 1000040501846, Monden, Nobuya, 1000030770143, Kudo, Naomi, Arai, Makoto, Sakurai, Daiju, 1000050361481, Asakage, Takahiro, Doi, Issei, Yamada, Takayuki, 1000030312359, and Homma, Akihiro

Abstract

Background To fill the data gap between clinical trials and real-world settings, this study assessed the overall effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) during Japanese real-world clinical practice. Methods This was a multicenter, retrospective study in Japanese patients with recurrent or metastatic HNC who received nivolumab for the first time between July and December 2017. Data on the clinical use, effectiveness, and safety of nivolumab were extracted from patient medical records. Results Overall, 256 patients were enrolled in this study. The median duration of nivolumab treatment was 72.5 days, with patients receiving a median of 6.0 (range 1-27) doses. Median overall survival (OS) was 9.5 (95% confidence interval [CI] 8.2-12.0) months and the estimated 12-month OS rate was 43.2%. The objective response rate (ORR) was 15.7% overall and 21.1%, 7.1%, and 13.6% in patients with primary nasopharynx, maxillary sinus, and salivary gland tumors, respectively, who had been excluded from CheckMate 141. Grade >= 3 immune-related adverse events occurred in 5.9% of patients. No new safety signals were identified compared with adverse events noted in CheckMate 141. Conclusions The effectiveness and safety of nivolumab in real-world clinical practice are consistent with data from the CheckMate 141 clinical trial. Therapeutic response was also observed in the groups of patients excluded from CheckMate 141.

Published
2021

23. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice : a multicenter retrospective clinical study

Author

Hanai, Nobuhiro, Shimizu, Yasushi, Kariya, Shin, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Yoshida, Masafumi, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Sakurai, Daiju, Asakage, Takahiro, Doi, Issei, Yamada, Takayuki, Homma, Akihiro, Hanai, Nobuhiro, Shimizu, Yasushi, Kariya, Shin, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Yoshida, Masafumi, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Sakurai, Daiju, Asakage, Takahiro, Doi, Issei, Yamada, Takayuki, and Homma, Akihiro

Abstract

Background To fill the data gap between clinical trials and real-world settings, this study assessed the overall effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) during Japanese real-world clinical practice. Methods This was a multicenter, retrospective study in Japanese patients with recurrent or metastatic HNC who received nivolumab for the first time between July and December 2017. Data on the clinical use, effectiveness, and safety of nivolumab were extracted from patient medical records. Results Overall, 256 patients were enrolled in this study. The median duration of nivolumab treatment was 72.5 days, with patients receiving a median of 6.0 (range 1-27) doses. Median overall survival (OS) was 9.5 (95% confidence interval [CI] 8.2-12.0) months and the estimated 12-month OS rate was 43.2%. The objective response rate (ORR) was 15.7% overall and 21.1%, 7.1%, and 13.6% in patients with primary nasopharynx, maxillary sinus, and salivary gland tumors, respectively, who had been excluded from CheckMate 141. Grade >= 3 immune-related adverse events occurred in 5.9% of patients. No new safety signals were identified compared with adverse events noted in CheckMate 141. Conclusions The effectiveness and safety of nivolumab in real-world clinical practice are consistent with data from the CheckMate 141 clinical trial. Therapeutic response was also observed in the groups of patients excluded from CheckMate 141.

Published
2021

27. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Author

Wakasaki, Takahiro, primary, Yasumatsu, Ryuji, additional, Masuda, Muneyuki, additional, Takeuchi, Toranoshin, additional, Manako, Tomomi, additional, Matsuo, Mioko, additional, Jiromaru, Rina, additional, Uchi, Ryutaro, additional, Komune, Noritaka, additional, Noda, Teppei, additional, and Nakagawa, Takashi, additional

Published
2020
Full Text
View/download PDF

30. Malignant perivascular epithelioid cell tumor mimicking jugular foramen schwannoma: A case report and literature review

Author

Komune, Noritaka, primary, Masuda, Shogo, additional, Yasumatsu, Ryuji, additional, Hongo, Takahiro, additional, Jiromaru, Rina, additional, Matsuo, Satoshi, additional, Akiyama, Osamu, additional, Tsuchihashi, Nana, additional, Matsumoto, Nozomu, additional, Yamamoto, Hidetaka, additional, and Nakagawa, Takashi, additional

Published
2020
Full Text
View/download PDF

33. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFRalteration and HPV infection in sinonasal squamous cell carcinoma

Author

Hongo, Takahiro, Yamamoto, Hidetaka, Jiromaru, Rina, Yasumatsu, Ryuji, Kuga, Ryosuke, Nozaki, Yui, Hashimoto, Kazuki, Matsuo, Mioko, Wakasaki, Takahiro, Tamae, Akihiro, Taguchi, Kenichi, Toh, Satoshi, Masuda, Muneyuki, Nakagawa, Takashi, and Oda, Yoshinao

Abstract

The antitumor efficacies of immune checkpoint inhibitors (ICIs) and the usefulness of potential predictive markers such as programmed death-ligand 1 (PD-L1) expression, density of tumor-infiltrating lymphocytes (TILs) and microsatellite instability (MSI) in sinonasal squamous cell carcinoma (SNSCC) have not been fully elucidated. We retrospectively analyzed 131 SNSCCs with immunohistochemistry for PD-L1 expression, TIL subpopulations and loss of mismatch repair (MMR) proteins as a surrogate for MSI-high. We also comprehensively evaluated the mutual relationships among these immuno-markers, high-risk human papillomavirus (HPV) infection, epidermal growth factor receptor(EGFR)gene status, and KRASmutation. PD-L1 expression (tumor proportion score ≥ 1%) was detected in 60 (45.8%) SNSCC cases and was significantly associated with worse overall survival (OS) (p= 0.0240). High density of cluster of differentiation 8 (CD8)-positive TILs was significantly associated with better progression-free survival (PFS) (p= 0.0368), and high density of forkhead box protein P3-positive TILs was significantly associated with better PFS and OS (p= 0.0007 and 0.0143, respectively). With respect to the combination of CD8 + TIL and PD-L1 expression, the high-CD8/PD-L1-negative group showed the most favorable prognosis, whereas the low-CD8/PD-L1-positive group showed the worst prognosis. MMR loss was detected in 3 (2.3%) of the 131 cases. HPV infection (6.1%), EGFRmutation (14.5%), EGFRcopy number gain (26%), and MMR loss were essentially mutually exclusive; patients in these molecular groups showed significant differences in prognosis but not in the degree of PD-L1 expression or TILs. Among the nine ICI-treated patients, three (33.3%) were responders, and the EGFR-wild type cases (n= 7) showed better clinical responses to an ICI compared to the EGFR-mutant cases (n= 2). Among the patients with residual/recurrent EGFR-wild type tumors (n= 43), ICI treatment significantly improved OS (p= 0.0281). The results suggest that the evaluation of immuno-markers and molecular subclassification may be helpful for prognostic prediction and selecting an individualized therapeutic strategy for patients with SNSCC.

Published
2021
Full Text
View/download PDF

38. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.

Author

Tomoyasu Yoshihiro, Kenji Tsuchihashi, Kenta Nio, Shuji Arita, Takafumi Nakano, Ryuji Yasumatsu, Rina Jiroumaru, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba, Yoshihiro, Tomoyasu, Tsuchihashi, Kenji, Nio, Kenta, Arita, Shuji, Nakano, Takafumi, Yasumatsu, Ryuji, Jiroumaru, Rina, and Ariyama, Hiroshi

Published
2017
Full Text
View/download PDF

48. Treatment of Hypopharyngeal Carcinomas-an Institutional Analysis of the Results of FAR Radiochemotherapy, Radical Resection, and Free Jejunum Flap Reconstruction and the Indication of Neck Dissection-

Author

Kuratomi, Yuichiro, primary, Yamanmoto, Tomoya, additional, Kumamoto, Yoshihiko, additional, Nakashima, Torahiko, additional, Masuda, Muneyuki, additional, Yasumatsu, Ryuji, additional, Koike, Kohji, additional, and Komiyama, Sohtaro, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results